Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial

Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial

© 2019 Wolters Kluwer Health, Inc. All rights reserved. Background:Bictegravir, coformulated with emtricitabine/tenofovir alafenamide as a fixed-dose combination (B/F/TAF), is recommended for treatment of HIV-1-infection. Multiple studies of B/F/TAF in treatment-naive and virologically suppressed co...

Full description

Saved in:
Bibliographic Details
Main Authors: Cissy Kityo, Debbie Hagins, Ellen Koenig, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Khuanchai Supparatpinyo, Natalya Gankina, Vadim Pokrovsky, Evgeny Voronin, Jeffrey L. Stephens, Edwin Dejesus, Hui Wang, Rima K. Acosta, Huyen Cao, Erin Quirk, Hal Martin, Tariro Makadzange
Format: Journal
Published: 2020
Subjects:
Medicine
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073178758&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/67951
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University

Similar Items

Similar Items